A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of a 12-week Treatment With BI 54903 at Doses of 181.8 Mcg b.i.d. and 363.6 Mcg q.d. (p.m. Dosing) Administered Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2011
At a glance
- Drugs BI 54903 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 22 Nov 2011 Actual initiation date Nov 2011 added as reported by ClinicalTrials.gov.
- 22 Nov 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 28 Oct 2011 New trial record